Literature DB >> 2254226

High prevalence of antibiotic resistant Escherichia coli in faecal samples of students in the south-east of The Netherlands.

M Bonten1, E Stobberingh, J Philips, A Houben.   

Abstract

From December 1988 to March 1989 172 faecal samples from first and second year students at the University of Limburg, Maastricht, The Netherlands, were collected and analysed for the presence of Escherichia coli strains resistant to ampicillin, sulphamethoxazole, tetracycline, trimethoprim and nitrofurantoin. In addition, the antibiotic susceptibility (MIC) to these agents and six other compounds (i.e. aminoglycosides, nitrofurantoin, nalidixic acid and cephalothin) was determined. The prevalence of resistance of the samples analysed ranged from 86% (i.e. 148 out of 172) for sulphamethoxazole to 25% for trimethoprim. The prevalence figures for ampicillin, tetracycline and nitrofurantoin resistance were 76%, 47% and 29%, respectively. The percentages of the faecal samples with a high proportion of E. coli (greater than 50% of the total number of E. coli) resistant to ampicillin, tetracycline and sulphamethoxazole were 8%, 11% and 37%, respectively. For nitrofurantoin and trimethoprim the figures were 3% and 1%, respectively. Of the isolated E. coli (n = 797), 84% was resistant to ampicillin, 82% resistant to sulphamethoxazole. The lowest percentages (9%) were observed for both nalidixic acid and nitrofurantoin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254226     DOI: 10.1093/jac/26.4.585

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Effects of flavophospholipol on resistance in fecal Escherichia coli and enterococci of fattening pigs.

Authors:  A E van den Bogaard; M Hazen; M Hoyer; P Oostenbach; E E Stobberingh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Monitoring of bactericidal action of laser by in vivo imaging of bioluminescent E. coli in a cutaneous wound infection.

Authors:  Samir Jawhara; Serge Mordon
Journal:  Lasers Med Sci       Date:  2006-08-03       Impact factor: 3.161

3.  Screening for antimicrobial resistance in fecal samples by the replica plating method.

Authors:  M Osterblad; T Leistevuo; P Huovinen
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

4.  Antimicrobial and mercury resistance in aerobic gram-negative bacilli in fecal flora among persons with and without dental amalgam fillings.

Authors:  M Osterblad; J Leistevuo; T Leistevuo; H Järvinen; L Pyy; J Tenovuo; P Huovinen
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

Review 5.  Bacterial resistance: new threats, new challenges.

Authors:  J C Pechère
Journal:  Support Care Cancer       Date:  1993-05       Impact factor: 3.603

6.  Trimethoprim resistance in South African isolates of aerobic gram-negative faecal flora.

Authors:  P V Adrian; H J Koornhof; B A Wylie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

7.  In vivo imaging of bioluminescent Escherichia coli in a cutaneous wound infection model for evaluation of an antibiotic therapy.

Authors:  Samir Jawhara; Serge Mordon
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

8.  The prevalence of antibiotic-resistant faecal Escherichia coli in healthy volunteers in Venezuela.

Authors:  H J van de Mortel; E J Jansen; G J Dinant; N London; E Palacios Prü; E E Stobberingh
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

9.  Trimethoprim resistant dihydrofolate reductases in normal faecal flora isolated in India.

Authors:  S Tait; S G Amyes
Journal:  Epidemiol Infect       Date:  1994-10       Impact factor: 2.451

10.  Antibiotic resistance of Escherichia coli in fecal samples of healthy people in two different areas in an industrialized country.

Authors:  M Bonten; E Stobberingh; J Philips; A Houben
Journal:  Infection       Date:  1992 Sep-Oct       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.